Patents Assigned to Octamer, Inc.
  • Patent number: 6326402
    Abstract: The present invention is directed to a method for inhibiting viral replication and treating viral infections by administering a pharmaceutically effective amount of a compound capable of binding a microtubule such as a diiodo thyronine analogue having no significant hormonal activity. The present invention also features novel pharmaceutical compositions comprising the same.
    Type: Grant
    Filed: August 12, 1998
    Date of Patent: December 4, 2001
    Assignee: Octamer, Inc.
    Inventors: Ernest Kun, Jerome Mendeleyev
  • Patent number: 6316495
    Abstract: A method for inhibition of retroviral replication by manipulation of enzyme adenosine diphosphoribosyl transferase which endogenously inhibits retroviral reverse transcriptase. The method is useful for prevention and treatment of retroviral infections, including HIV. The inhibition of the viral replication is achieved by administration to a mammal susceptible to or infected with a retrovirus drugs which specifically inhibit poly-ADP-ribosylation of adenosine diphosphoribosyl transferase.
    Type: Grant
    Filed: January 8, 1999
    Date of Patent: November 13, 2001
    Assignee: Octamer, Inc.
    Inventors: Ernest Kun, Kalman G. Buki
  • Patent number: 6303621
    Abstract: The present invention is directed to a method for treating cancers by administering a pharmaceutically effective amount of a diiodo thyronine analogue having no significant hormonal activity and a vinca alkaloid or biologically active analog thereof. The present invention also features novel pharmaceutical compositions comprising the same.
    Type: Grant
    Filed: April 21, 1999
    Date of Patent: October 16, 2001
    Assignee: Octamer, Inc.
    Inventor: Ernest Kun
  • Patent number: 6303629
    Abstract: The present invention is directed to a method for treating inflammation or inflammatory disease, bacterial infection, arthritis and stroke in an animal or mammal, which comprises the steps of administering an effective amount of a pADPRT inhibitory compound to said animal or mammal.
    Type: Grant
    Filed: April 6, 1998
    Date of Patent: October 16, 2001
    Assignee: Octamer, Inc.
    Inventor: Ernestt Kun
  • Patent number: 6017958
    Abstract: The present invention provides methods for treating cancer, particularly malignant tumors, with thyroxine analogues having no significant hormonal activity. A thyroxine analogue is administered to an afflicted mammal in an amount effective to cause depression or regression of malignant tumor growth or to treat cancer. Particularly preferred thyroxine analogues are those capable of causing about 35 percent or more inhibition of initial velocity of microtubule protein assembly in vitro.
    Type: Grant
    Filed: April 3, 1997
    Date of Patent: January 25, 2000
    Assignee: Octamer, Inc.
    Inventors: Ernest Kun, Jerome Mendeleyev
  • Patent number: 6004978
    Abstract: Unsubstituted or substituted halo nitro and nitroso compounds and their metabolites are potent, selective and non-toxic inhibitors and suppressants of cancer growth and viral infections in a mammalian host. The compounds are particularly useful for treatment and suppression of tumors and viruses associated with breast cancer, AIDS, herpetic episodes and cytomegaloviral infections. The methods of treatment of tumorigenic and viral diseases by halo nitro and nitroso compounds and their metabolites are described.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: December 21, 1999
    Assignee: Octamer, Inc.
    Inventors: Ernest Kun, Jerome Mendeleyev, Eva Kirsten
  • Patent number: 5922775
    Abstract: The present invention provides methods for treating cancer, particularly malignant tumors, with ketone thyroxine analogues having no significant hormonal activity. A ketone thyroxine analogue is administered to an afflicted mammal in an amount effective to cause depression or regression of malignant tumor growth or to treat cancer. Particularly preferred ketone thyroxine analogues are those capable of causing about 35 percent or more inhibition of initial velocity of microtubule protein assembly in vitro.
    Type: Grant
    Filed: October 23, 1997
    Date of Patent: July 13, 1999
    Assignee: Octamer, Inc.
    Inventors: Ernestt Kun, Jerome Mendeleyev, Kalman G. Buki
  • Patent number: 5908861
    Abstract: The present invention is directed to a method for treating inflammation or inflammatory disease in an animal or mammal, which comprises the steps of administering an effective amount of an pADPRT inhibitory compound to said animal or mammal.
    Type: Grant
    Filed: May 13, 1997
    Date of Patent: June 1, 1999
    Assignee: Octamer, Inc.
    Inventor: Ernestt Kun
  • Patent number: 5877185
    Abstract: The subject invention provides for novel synergistic compositions useful for inactivating viruses or inducing apoptosis in tumor cells and for treating cancer or retroviral infections. Generally, the compositions comprise one or a plurality of ligands that oxidatively attack a zinc finger of pADPRT in combination with one or a plurality of agents selected from the group consisting of: agents that decrease cellular levels of glutathione and ligands that non-covalently bind to the nicotinamide site of pADPRT but do not effect zinc ejection from a zinc finger of pADPRT.
    Type: Grant
    Filed: January 13, 1995
    Date of Patent: March 2, 1999
    Assignee: Octamer, Inc.
    Inventors: Ernest Kun, Jerome Mendeleyev, Eva Kirsten
  • Patent number: 5753674
    Abstract: The subject invention provides for novel compounds for inactivating viruses. These compounds include 6-nitroso-1,2-benzopyrone, 3-nitrosobenzamide, 5-nitroso-1 (2H)-isoquinolinone, 7-nitroso-1(2H)-isoquinolinone, 8-nitroso-1 (2H)-isoquinolinone. The invention also provides for compositions containing one or more of the compounds, and for methods of treating viral infections, cancer, infectious virus concentration with the subject compounds and compositions.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: May 19, 1998
    Assignee: Octamer, Inc.
    Inventors: Ernest Kun, Jerome Mendeleyev, William C. Rice
  • Patent number: 5736576
    Abstract: The present invention provides methods for treating cancer, particularly malignant tumors, with thyroxine analogues having no significant hormonal activity. A thyroxine analogue is administered to an afflicted mammal in an amount effective to cause depression or regression of malignant tumor growth or to treat cancer.
    Type: Grant
    Filed: June 4, 1996
    Date of Patent: April 7, 1998
    Assignee: Octamer, Inc.
    Inventors: Ernest Kun, Jerome Mendeleyev
  • Patent number: 5652260
    Abstract: The subject invention provides for novel compounds for inactivating viruses. These compounds include 6-nitroso-1,2-benzopyrone, 3-nitrosobenzamide, 5-nitroso-1(2H)-isoquinolinone, 7-nitroso-1(2H)-isoquinolinone, 8-nitroso-1(2H)-isoquinolinone. The invention also provides for compositions containing one or more of the compounds, and for methods of treating viral infections, cancer, infectious virus concentration with the subject compounds and compositions.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: July 29, 1997
    Assignee: Octamer, Inc.
    Inventors: Ernest Kun, Jerome Mendeleyev, William C. Rice
  • Patent number: 5583155
    Abstract: Unsubstituted or substituted 6-amino-1,2-benzopyrones are potent, selective and non-toxic inhibitors and suppressants of viral infections in a mammalian host. The compounds are particularly useful for treatment of AIDS, herpetic episodes and cytomegaloviral infections. The method of treatment of viral diseases by 6-amino-1,2-benzopyrones is described.
    Type: Grant
    Filed: May 3, 1994
    Date of Patent: December 10, 1996
    Assignee: Octamer, Inc.
    Inventors: Ernest Kun, Laure Aurelian
  • Patent number: 5519053
    Abstract: Unsubstituted or substituted 5-iodo-6-amino-1,2-benzopyrones and their metabolites are potent, selective and non-toxic inhibitors and supressants of cancer growth and viral infections in a mammalian host. The compounds are particularly useful for treatment and supression of tumors and viruses associated with AIDS, herpetic episodes and cytomegaloviral infections. The methods of treatment of tumorigenic and viral diseases by 5-iodo-6-amino-1,2-benzopryrones and/or its metabolites are described.
    Type: Grant
    Filed: February 24, 1993
    Date of Patent: May 21, 1996
    Assignee: Octamer, Inc.
    Inventors: Ernest Kun, Jerome Mendeleyev
  • Patent number: 5516941
    Abstract: The subject invention provides for novel compounds for inactivating viruses. These compounds include 6-nitroso-1,2-benzopyrone, 3-nitrosobenzamide, 5-nitroso-1(2H)isoquinolinone, 7-nitroso-1(2H)-isoquinolinone, 8-nitroso-1(2H)-isoquinolinone. The invention also provides for compositions containing one or more of the compounds, and for methods of treating viral infections, cancer, infectious virus concentration with the subject compounds and compositions.
    Type: Grant
    Filed: November 2, 1992
    Date of Patent: May 14, 1996
    Assignee: Octamer, Inc.
    Inventors: Ernest Kun, Jerome Mendeleyev
  • Patent number: 5482975
    Abstract: The subject invention provides for novel compounds for inactivating viruses. These compounds include 6-nitroso-1,2-benzopyrone, 3-nitrosobenzamide, 5-nitroso-1(2H)-isoquinolinone, 7-nitroso-1(2H)isoquinolinone, 8-nitroso-1(2H)isoquinolinone. The invention also provides for compositions containing one or more of the compounds, and for methods of treating viral infections, cancer, infectious virus concentration with the subject compounds and compositions.
    Type: Grant
    Filed: February 24, 1993
    Date of Patent: January 9, 1996
    Assignee: Octamer, Inc.
    Inventors: Ernest Kun, Jerome Mendeleyev
  • Patent number: 5464871
    Abstract: Unsubstituted or substituted halo nitro and nitroso compounds and their metabolites are potent, selective and non-toxic inhibitors and supressants of cancer growth and viral infections in a mammalian host. The compounds are particularly useful for treatment and supression of tumors and viruses associated with breast cancer, AIDS, herpetic episodes and cytomegaloviral infections. The methods of treatment of tumorigenic and viral diseases by halo nitro nitroso compounds and their metabolites are described.
    Type: Grant
    Filed: June 11, 1993
    Date of Patent: November 7, 1995
    Assignee: Octamer, Inc.
    Inventors: Ernest Kun, Jerome Mendeleyev, Eva Kirsten
  • Patent number: 5262564
    Abstract: The subject invention provides for novel anti-tumor and anti-retroviral compounds. More specifically, the invention relates to the sulfinic acid adducts of therapeutic C-nitroso compounds. The formation of the adducts increases the stability and more solubility of the C-nitroso compounds. These compounds include the L-cysteinesulfinic acid adducts of 6-nitroso-1,2-benzopyrone and 3-nitrosobenzamide. The invention also provides for compositions containing one or more of the compounds, and for methods of treating retroviral infections, cancer, infectious virus concentration with the subject compounds and compositions.
    Type: Grant
    Filed: October 30, 1992
    Date of Patent: November 16, 1993
    Assignee: Octamer, Inc.
    Inventors: Ernest Kun, Jerome Mendeleyev